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Hello, my name is Umyeena Bashir, I am a Graduate student studying Organic Chemistry under
Dr. Herman Nikolayevskiy. I will be presenting my current research on the development of
Covalent inhibitors against sortase A activity in staphylococcus aureus bacteria.
Currently, there has been a rise in MRSA induced hospitalization, which is of great concern.
Widely used antibiotics that are normally administered to treat staph infections, which are
otherwise easily treatable, are no longer effective. This rise in MRSA has spiked interest in the
science community to develop novel antibiotics against staph infections. However, with the
majority of antibiotics designed with mechanisms that impact bacterial nuclear functions, this
bacteria will continue to develop resistance towards these newer antibiotics, leading to the
undesired side effect of creating a superbug. Therefore, our laboratory is delving into other
pathways to inhibit staphylococcus aureus. By developing an inhibitor that does not kill the
bacteria but rather inhibits virulent activity, we can avoid the development of resistance. We are
currently working towards the development of covalent inhibitors of Sortase A, a bacterial
enzyme responsible for virulence but not necessary for bacterial survival.
S.aureus requires the use of adhesive surface proteins to latch onto its target in order to inject
toxins into the host. These surface proteins are called pilin and are attached to the outer cell
membrane of S aureus through the transpeptidase activity of sortase A, a cysteine protease.
This enzyme is essential in maintaining s. aureus virulence and recent publications have shown
that blocking this enzyme’s function inhibits the ability of S. aureus to infect. Since inhibition of
Sortase A does not kill the bacterium, our virulence-targeting strategy should prevent S. aureus
from developing resistance to these types of antibiotics.
How we have decided to approach our research design has been widely inspired by the findings
of researchers at the Latvian Institute of Organic Chemistry, where they have screened a wide
range of Sortase A inhibitors, finding one in particular to have promise as a low toxicity covalent
inhibitor. This molecule, shown in figure 1.11, has been the inspiration and starting point of our
research as we plan to design molecular derivatives of this compound that will essentially have
faster rate of inhibition as well as increased intermolecular interactions that better the inhibitory
effect of this antibiotic molecule.
To narrow down the vast chemical space of possibilities, our lab uses molecular docking
software to computationally evaluate potential antibiotic derivatives before synthesizing
them.With the multitude of options readily available for docking, we have decided to evaluate
the platform Medusa Dock since it offers the ability to set distance constraints, reinforced by an
energy bonus.
However, since medusa dock does not offer users the ability to specify docking position
accurately, we had to evaluate the accuracy of this software. Using PDB protein file 2MLM and
its docked published inhibitor 2W7, shown in figure 2, we evaluated how accurately Medusa
Dock was able to replicate the published docking structure (figures 3-5). We changed
constraints values as well as energy bonuses to see which range of user set constraints would
give the closest result (table 1). We discovered that by setting fairly flexible distances for
docking but higher energy bonuses, we received the most accurate docking results.
Taking this knowledge, we then ultimately decided to see how accurately this platform could
covalently dock by seeing if Medusa Dock could replicate the published nmr results of PDB
docked ligand-protein complex 6R1V. Unfortunately, this software was unable to give us
accurate results, as shown in figures 7-9. As our project continues, we plan to look into other
docking software and evaluate their ability to covalently dock as well as looking into the
intermolecular interactions of the docked ligand-protein structure of inhibitor 26 and design
some derivatives for docking.
Thank you for listening to my poster presentation. I would like to recognize Dr. Herman
Nikolayevskiy and the Nikolayevskiy lab, as well as the chemistry department at USF.
